Example: air traffic controller
NEW ZEALAND DATA SHEET - Medsafe
1 NEW ZEALAND DATA SHEET 1. PRODUCT NAME Ventolin Inhaler (CFC-Free) 100 micrograms 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Ventolin Inhaler (CFC-Free) is a pressurised metered-dose inhaler which delivers
Tags:
Information
Domain:
Source:
Link to this page:
Documents from same domain
ADVANTAN Presentation Uses - Medsafe
www.medsafe.govt.nzADVANTAN® Data Sheet Page 1 of 9 ADVANTAN® Methylprednisolone aceponate 0.1% ointment/cream . Presentation 1 g cream or ointment contains 1 mg (0.1%) methylprednisolone aceponate.
LOXALATE 1. Product Name - Medsafe Home Page
www.medsafe.govt.nzPage 5of 21 at risk, such as the elderly, or patients with cirrhosis, or if used in combination with other medications which may cause hyponatraemia.
DATA SHEET 1 CLEXANE AND CLEXANE FORTE ... - …
www.medsafe.govt.nzNew Zealand Data Sheet June 2017 . clexane-clexane-forte-ccdsv13-dsv18-16jun17 Page 2 . 100 mg injection enoxaparin sodium 100mg (equivalent to …
SEPTANEST Articaine hydrochloride 4% with …
www.medsafe.govt.nzSEPTANEST Articaine hydrochloride 4% with adrenaline 1:100,000 Injection for local and regional dental anaesthesia DESCRIPTION SEPTANEST is a sterile aqueous solution that contains articaine hydrochloride 4% (40 mg/mL) with adrenaline acid tartrate in a 1:100,000 strength.
BOOSTRIX - Medsafe Home Page
www.medsafe.govt.nz1 BOOSTRIX®. Combined diphtheria, tetanus, acellular pertussis (dTpa) vaccine . CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET? This leaflet answers some of the common questions about BOOSTRIX vaccine.
NEW ZEALAND DATA SHEET - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET Cymevene ® DS 170831 2 of 26 Caution: Cymevene must only be administered by IV infusion over 1 hour, preferably via a
Edition Draft - Medsafe
www.medsafe.govt.nzPart 4, Ed Draft Page 2 of 9 Section 1: Good Manufacturing Practice Documentation 1.1. When is GMP Documentation Required? Medsafe requires evidence of Good Manufacturing Practice (GMP) compliance for
Data Sheet 1 PRODUCT NAME 2 QUALITATIVE AND …
www.medsafe.govt.nzNew Zealand Data Sheet 31 July 2017 Lantus – insulin glargine lantus-ccdsv19-dsv11-31jul17 Page 1 Data Sheet 1 PRODUCT NAME Lantus 100 IU/mL solution for injection in 10 …
NEW ZEALAND DATA SHEET MESTINON® - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET MESTINON® MESTINON Page 4 of 8 As the severity of myasthenia gravis often fluctuates considerably, particular care is required to
DATA SHEET PREDNISONE - Medsafe
www.medsafe.govt.nz• Epilepsy and/or seizure disorder • Peptic ulceration • Previous steroid myopathy • Tuberculosis • Patients with myasthenia gravis receiving anticholinesterase therapy since
Related documents
4. ESSENTIAL NUTRIENTS IN DRINKING WATER
www.who.int43 of functional impairment. Recently FAO/WHO defined recommended nutrient intake (RNI) as “the daily intake, which meets the nutrient requirements of almost all (97.5 percent) apparently
Intraluminal Volume Dose Alteplase for the Clearance of ...
www.thomasland.com204 Volume 50, March 2015 Intraluminal Alteplase for Occluded PICC Lines time first dose of alteplase administered, time second dose of alteplase administered (if applicable), time
3 CT Parameters that Influence the Radiation Dose
www.sascrad.com1 3 CT Parameters that Influence the Radiation Dose Hans Dieter Nagel, PhD Philips Medical Systems, Science and Technology, Roentgenstr. 24, D-22335 Hamburg, Germany
á232ñ ELEMENTAL IMPURITIES—LIMITS
www.usp.orgElement Table 1. Permitted Daily Exposures for Elemental ImpuritiesClass (Continued) Oral PDE (mg/day)Parenteral PDE (mg/day)Inhalation PDE (mg/day)Silver 2B 150 10 7 Platinum 2B 100 10 1
Naltrexone Side Effects and Efficacy in GI Disorders
www.gidoctor.netLow Dose Naltrexone: Side Effects and Efficacy in Gastrointestinal Disorders Ploesser J, Weinstock LB, Thomas E International Journal of Pharmaceutical Compounding; March 2010
Validation of a Questionnaire for Assessing Adherence to ...
www.neumologia-pediatrica.comherence can cause therapeutic failure, need to increase medication dosage or add other medications, need for costly diagnostic testing, and unnecessary morbidity and even mortality.1,2 Self-report of asthma medication use by the patient (or by parents or caregivers in the case of children)
Salmeterol xinafoate (25 mcg per metered actuation).
www.medsafe.govt.nz1 NEW ZEALAND DATA SHEET SEREVENT ® Inhaler (CFC-Free) Salmeterol xinafoate (25 mcg per metered actuation). Presentation SEREVENT Inhaler Free) consists of …